Expression of the miR-200 family in tumor tissue, plasma and urine of epithelial ovarian cancer patients in comparison to benign counterparts

BMC Research Notes

Antti Ilvesmäki¹  Annika Auranen¹  Synnöve Staff¹  Kalle Savolainen¹  Johanna U. Mäenpää¹  Mauro Scaravilli²  Tapio Visakorpi²  Teemu Tolonen² 

[1] Department of Obstetrics and Gynecology, Tampere University Hospital;Tays Cancer Centre, Tampere University Hospital and Tampere University;

关键词: Ovarian cancer;    HGSOC;    microRNA;    Liquid biopsy;    Biomarker;   

DOI  :  10.1186/s13104-020-05155-6

来源: DOAJ

【 摘 要 】

Abstract Objective Plasma, but also urine sample could represent a simple liquid biopsy for ovarian cancer biomarker detection. The miRNA-200 family has been shown to be dysregulated in ovarian cancer. The aim of this study was to isolate three members of miR-200 family from tumor tissue, plasma and urine of high-grade serous ovarian cancer patients in comparison with samples from patients with benign ovarian tumors. This is a methodological pilot study of a prospective ovarian cancer patient cohort investigating the potential of liquid biopsies and the role of miRNAs in ovarian cancer treatment. Results MiR-200a, miR-200b and miR-200c were isolated from samples of nine ovarian cancer patients and seven patients with benign ovarian tumor. The most significant finding is that all three miRNAs were detectable in all sample types. Tumor tissue and plasma, but not urine analysis was able to discriminate malignant and benign samples. A correlation between the miRNA-200 expression in urine and plasma was observed in malignant samples only. Plasma and urine with respect to miRNA detection show potential according to this study, but larger studies are needed to clarify the usefulness of these liquid biopsies in ovarian cancer. Trial registration: ClinicalTrials.gov NCT02758652, May 2, 2016.

【 授权许可】

Unknown